Arc Institute Virtual Cell AI
Virtual cell AI from Arc Institute could reshape biological research and drug discovery with predictive models.
Biotech & Health
Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Posts tagged with Biotech & Health
Big Picture Bio’s £2.2M World Model for Cancer Combinations: 86% ASCO Call Rate
86% of 14 ASCO phase-3 calls posted the day before readout. That is the early proof point for a generative world model aimed at synergistic sequences, not single-target ranking.
51 Trials, 16 Aging Clocks, and the $101M Measurement Gap
TranslAGE pooled 51 interventional studies and ran 16 clocks plus 94 further biomarkers across all of them. Chronological-age clocks moved sporadically; one held up everywhere. Mortality-trained clocks all fell and agreed. Gastric bypass cut a metabolic score by 0.43 without moving a general clock.
Omnio's €2.9M plasminogen bet on diabetic foot ulcers: credible mechanism, unproven market
Omnio AB closed an oversubscribed €2.9 million round in Umeå on 1 October 2026, funding a master cell bank, a GMP batch and the toxicology package for a Phase I/IIa study in diabetic foot ulcers targeted for 2027. The plasminogen mechanism has independent support in human wound fluid.
BioOra Raises NZ$30M, Signs a CAR T Licence, and Targets a 2028 ASX Listing
BioOra secured NZ$30 million in the first close of Series A2 and signed a definitive global licence for the WZTL-002 CAR T construct. NZ$15 million still has to arrive before December, and a Medsafe filing decides the 2028 ASX plan.
Kither's 42-Amino-Acid Peptide Targets the COPD Pathway Merck Bought for $10 Billion
Kither Biotech started dosing COPD patients with KIT2014, a 42-amino-acid inhaled peptide that blocks PDE3 and PDE4 and, on the available evidence, does not leave the lung. The pathway Merck paid $10 billion for is de-risked. Getting a different molecule to stay put in the airway is not.
PDS0101's Survival Number Outlived Its Own Phase 3
A single-arm Phase 2 gave 53 patients PDS0101 plus pembrolizumab and reported 39.3-month median overall survival in JAMA Oncology. Five weeks earlier the company had terminated the confirmatory Phase 3 at 12 patients, citing financial constraints alone.
AnaCardio's €62.5M Series B Bets a Safer Inotrope Can Reopen Heart Failure
AnaCardio closed a €62.5M Series B co-led by Novo Holdings to move AC01 toward Phase 3. A 58-patient Lancet study showed a clean safety signal and better cardiac output — not yet the outcomes that decide whether a heart drug works.